Search results
Pfizer to test third dose of COVID-19 vaccine in children
AOL· 5 days agoThe decision was made after an analysis showed the two-dose vaccine generated an immune response in...
Pfizer pauses phase 3 dosing in gene therapy trial after young boy's death
FierceBiotech· 6 days agoA young boy with Duchenne muscular dystrophy (DMD) participating in Pfizer’s phase 2 gene therapy...
Will your last COVID vaccine work against new ‘FLiRT’ variants?
WJZY via Yahoo News· 23 hours agoBoth FLiRT variants are considered very similar to JN.1, health...spread as the summer months...
AstraZeneca pulls Covid vaccine after admitting rare side effect
Daily Express· 6 days agoThe Oxford-AstraZeneca Covid vaccine is set to be withdrawn after the pharmaceutical giant admitted...
Pfizer reports patient death in Duchenne gene therapy study
Reuters via Yahoo News· 6 days ago(Reuters) -A young patient died due to cardiac arrest after receiving Pfizer's experimental gene...
Will withdrawal of AstraZeneca vaccine affect your next COVID booster jab?
Yahoo News UK· 5 days agoAgency advice on bookings set out the vaccines that would be used. The guidance said that only mRNA ...
Enanta Pharmaceuticals Inc (ENTA) (Q2 2024) Earnings Call Transcript Highlights: Navigating ...
GuruFocus.com via Yahoo Finance· 6 days agoQ: What doses of EDP-323 are you testing in the Phase IIa human challenge study? A: Jay Luly responded that they are testing two regimens: one with a consistent 600 mg dose
Market Today: Pfizer Pauses Gene Therapy Trial After Patient Dea
Guru Focus· 6 days agoThe stock market exhibited mixed results at the close today. The Nasdaq Composite edged down by...
Bird Flu: 100 Million Doses of Vaccine Could Be Shipped Within Months
Healthline· 6 days agoThe U.S. government has two candidate vaccine viruses for H5N1 bird flu that could be used to make...
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Benzinga· 6 days agoValneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates Q1 financial highlights Total revenues of €32.8 million, including sales of €32.1 million, on track to meet